Excelimmune, a Woburn, MA-based developer of a human recombinant polyclonal antibody-based drugs, announced today that it had wrapped up a $10.5 million Series B financing, from new and previous high net worth individual backers. The money will go to enhancing Excelimmune’s discovery platform and manufacturing processes, and toward development of Staphguard, the company’s treatment for Staph infections resistant to methicillin. Last July Excelimmune brought in $4.5 million in equity financing from two investors.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
